ETON•benzinga•
Eton Pharmaceuticals Announces Results From Bioequivalence Study Of ET-600 For Treatment Of Central Diabetes Insipidus; To Submit New Drug Application In April 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 14, 2025 by benzinga